Formulary Limitations and the Elderly: Results from the Managed Care Outcomes Project
According to this article, the elderly are at particular risk from formulary restrictions, an important issue as more Medicaid and Medicare patients enroll in managed care. In fact, selecting less expensive drugs may lead to greater side effects in the elderly.
The article details a study that examined whether restrictive formularies are associated with differences in health care resource utilization, including number of office visits, prescriptions and hospitalizations, and whether this association varies by age. The authors conclude that common strategies for decreasing drug expenditures may be associated with higher severity-adjusted resource utilization. In specific areas, this association is more pronounced in the elderly.
Evidence, Coverage and Incentives: Challenges in Personalized Medicine
Personalized medicine is greatly changing the way medicine is practiced, as well as how drugs and biologics are developed. Today patients are...
Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?
A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...Framework Helps ACOs Leverage Pharmaceuticals to Realize Quality, Cost Goals
Medications are more than an item on the balance sheet for health care providers. Pharmaceuticals offer a route to manage costs while achieving...Comparative Effectiveness Research and the Changing Health Care Landscape
This content appeared in the January 2, 2012 print edition of Chain Drug Review. In the span of just one year, the health care landscape has...
NBCH eValue8™ Report Reveals Health Plans’ Ability to Align Employee Incentives to Improve Health
Washington, DC (November 30, 2009) – The current rate of health care cost increases are unsustainable and health care purchasers are increasingly...Leaders in Healthcare to Examine Impact of Comparative Effectiveness Research on Personalized Medicine
Arlington, VA (October 27, 2009)—As Congress continues its efforts to reform the health care system, the National Pharmaceutical Council (NPC) and...Comparative Effectiveness Research Can Enhance Quality, Value of Patient Care
Washington, DC. (September 10, 2009) – In response to President Obama’s health care reform address to Congress, National Pharmaceutical Council...National Pharmaceutical Council Says Comparative Effectiveness Research Can Improve Patient Outcomes; Requires Thoughtful Prioritization, Rigorous Research Methods, and Integration With Provider Decision Support
Washington, DC. (June 17, 2009) — Speaking at the National Pharmaceutical Council’s (NPC) symposium today, NPC President Dan Leonard said it’s...Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?
A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...Framework Helps ACOs Leverage Pharmaceuticals to Realize Quality, Cost Goals
Medications are more than an item on the balance sheet for health care providers. Pharmaceuticals offer a route to manage costs while achieving...Comparative Effectiveness Research and the Changing Health Care Landscape
This content appeared in the January 2, 2012 print edition of Chain Drug Review. In the span of just one year, the health care landscape has...CER: Who Can Say What, and When Can They Say It?
With billions of dollars in comparative effectiveness research (CER) set for completion in coming years, there will be broader discussions about the...
Comparative Effectiveness Research in Medicare Decision-Making
At the June 2011 Drug Information Association Annual Meeting, NPC asked Dr. Marcel Salive for his thoughts on how comparative effectiveness research...Evidence, Coverage and Incentives: Challenges in Personalized Medicine
Personalized medicine is greatly changing the way medicine is practiced, as well as how drugs and biologics are developed. Today patients are...Research
Why the Elderly Need Individualized Pharmaceutical Care
A “one drug fits all” approach does not work for eld
Coordinated Pharmaceutical Therapy in Chronic Care: Five Innovative Programs (Executive Summary)
Numerous studies indicate the limitations of a compo
Coordinated Pharmaceutical Therapy in Chronic Care: Five Innovative Programs
Improving the coordination of pharmaceutical care, e
- 1 of 33
- >
Commentary & Testimony
Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?
Framework Helps ACOs Leverage Pharmaceuticals to Realize Quality, Cost Goals
Comparative Effectiveness Research and the Changing Health Care Landscape
CER: Who Can Say What, and When Can They Say It?
Medicare Part D, Adherence, and the Value of Pharmaceuticals